July 29, 2019
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

Watch for our special post-NRG19 meeting e-mail blast coming out later this week!


ACTIVATIONS

GYNECOGLOGIC

NRG-GY018: Reopened to accrual with Amendment 1. Version date: July 3, 2019. Pending IRB approval of amendment 1, the study is open to enrollment. (posted on CTSU)

 

AMENDMENTS

GYNECOLOGIC

GOG-0238: Amendment 15; version date: May 28, 2019 (posted on CTSU)


CLOSURES

GYNECOLOGIC

GOG-0237: REMINDER - Closing to accrual as of 5pm ET August 1, 2019 (memo posted on NRG Oncology)

FORM UPDATES

GENITOURINARY

RTOG 1115: A new blank version (1.012) of case report forms, dated July 25, 2019, have been updated and posted to the CTSU website.  Please start using these immediately.

 

 OTHER PROTOCOL NOTICES

1.       BRAIN

CCTG CE.7: Updated Patient Recruitment/Patient Education Materials are available on the CTSU website (CIRB Documents>Amendment Reviews>Support Documents 1 and 2, and 3). NRG Oncology sites are encouraged to enroll to the trial and credit NRG Oncology. Please contact the NRG Oncology Study Chair, Dr. Vinai Gondi, or the NRG Oncology Study Champion, Dr. Minesh Mehta, with questions.

 

 2.    GYNECOLOGIC

NRG-GY009: Block Submission Reminder memo (posted on CTSU)

 

Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus   Read more

 

Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment Read more

 

 

3.    VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, August 14.

 

DRUG SAFETY UPDATES AND INVESTIGATOR BROCHURE (IB) NOTICES

Safety updates and IB Notices have been issued for the following studies:

DRUG NAME

PROTOCOL

WEBSITE FOR SAFETY REPORTS

IB*

Ceritinib

NRG-LU003

CTSU

X

Nivolumab

NRG-BN002

NRG-GY003

NRG

NRG

 

Pembrolizumab

NRG-GY016

NRG- HN003

CTSU

NRG

 

 

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Online Agent Order Processing (OAOP) website.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

 

NRG Oncology is seeking an experienced Patient Advocate to serve as Chair for its Patient Advocate Committee

This volunteer position provides the selected individual the responsibility of facilitating and guiding the NRG Oncology Patient Advocate Committee (PAC) and program through a process to update its vision and create an action plan to build on its success. Read more


NRG Oncology meeting with FDA
Oncology Center for Excellence

Members of NRG Oncology's leadership team recently met with leadership from the FDA Oncology Center for Excellence to advance our collaborations in our cancer clinical trials research. The agenda included an overview of our portfolio, a discussion of several registry – intent studies and the successes and challenges in developing and conducting those. Topics included navigating international collaborations, best practices in developing and conducting registry-intent trials, and issues frequently raised by our members such as the use of bio-similars. Although this was not the forum to address protocol-specific issues, the meeting resulted in greater clarity on mechanisms in place to help navigate those questions, items which are in need of more comprehensive guidance, and underscored our mutual interest in improving outcomes for cancer patients.

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

ACCEPTED MEETING ABSTRACT

CNS (Congress pf Neurological Surgeons) Oct 19-23, 2019

Wefel J, Pugh SL, Gondi V, Brown P, Tome WA, Armstrong T, Bruner D, Bovi JA, Robinson C, Khuntia D, Grosshans D, Konski A, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Mehta MP, Kachnic LA. NRG CC001 Neurocognitive Final Analysis. CNS (Congress of Neurological Surgeons). accepted as an Interactive Multimedia Research Presentation


PUBLICATIONS REMINDERS

Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings

American Society for Radiation Oncology (ASTRO); Sep 15-18, 201 9; Chicago, IL

International Gynecologic Cancer Society (IGCS); Sep 19-20, 2019; Rio de Janeiro, Brazil

International Society for Quality of Life Research (ISOQOL); Oct 20-23, 2019; San Diego, CA

Society for Neuro -Oncology (SNO) Inaugural Conference on Brain Metastases; Aug 16-17, 2019; New York City, NY


Upcoming Abstract Submission Deadlines

European Society for Medical Oncology (ESMO); Sep 27-Oct 1, 2019; Barcelona, Spain; LBA Aug 21, 2019 9:00 pm CEST

San Antonio Breast Cancer Symposium (SABCS); Dec 10-14, 2019; San Antonio, TX; LBA Aug 30, 2019

 

NRG Oncology is proud to be an active participant of #CancerMoonShot.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse